资料显示，南京麦澜德医疗科技股份有限公司位于江苏省南京市雨花台区凤展路32号A2栋，成立日期 2013年1月16日，上市日期2022年8月11日，公司主营业务涉及从事盆底及产后康复领域相关产品的研 发、生产、销售和服务。主营业务收入构成为：盆底康复产品36.98%，生殖康复产品33.10%，耗材及 配件24.32%，运动康复产品2.77%，其他(补充)2.18%，其他产品0.66%。 截至6月30日，麦澜德股东户数5461.00，较上期增加10.84%；人均流通股6743股，较上期减少9.78%。 2025年1月-6月，麦澜德实现营业收入2.41亿元，同比增长5.62%；归母净利润6392.01万元，同比减少 11.96%。 10月10日，麦澜德跌1.78%，成交额6179.31万元。两融数据显示，当日麦澜德获融资买入额914.28万 元，融资偿还1099.95万元，融资净买入-185.67万元。截至10月10日，麦澜德融资融券余额合计1.33亿 元。 分红方面，麦澜德A股上市后累计派现2.68亿元。 融资方面，麦澜德当日融资买入914.28万元。当前融资余额1.33亿元，占流通市值的8.83%，融资余额 超 ...

Key Points - The article highlights various significant announcements from different companies, including project investments, performance data, and stock buybacks [1][2][3][4] Group 1: Company Announcements - 麦湖德's revenue from sports rehabilitation products is currently a small proportion of its total income [1] - 达实智能 signed a smart hospital project worth 90.7533 million yuan [1] - 特锐德 is expected to win a railway project worth approximately 144 million yuan [1] - 罗牛山 reported a sales revenue of 97.5029 million yuan from pig sales in July [2] - *ST星农 plans to acquire 100% equity of 中城汽车 [1][3] - 陕西金叶 intends to repurchase shares worth between 40 million and 70 million yuan [1][3] - 贵州茅台's net profit for the first half of the year reached 45.403 billion yuan, a year-on-year increase of 8.89% [1][3] - 天亿马's shareholders plan to reduce their holdings by up to 3.46% [1][3] - 江苏索普 plans to raise no more than 1.5 billion yuan through a private placement [4] Group 2: Performance Data - 道氏技术 reported a net profit of 230 million yuan for the first half of the year, a year-on-year increase of 108.16% [3] - 鹏鼎控股's net profit for the first half of the year was 1.233 billion yuan, reflecting a year-on-year growth of 57.22% [3] - 金龙鱼 achieved a net profit of 1.756 billion yuan in the first half of the year, a year-on-year increase of 60.07% [3] - 中国联通's net profit for the first half of the year was 6.349 billion yuan, up by 5.1% year-on-year [3]

智通财经APP讯，麦澜德(688273.SH)发布股价异动公告称，公司主要从事盆底及妇产康复领域相关医 疗器械产品的研发、生产、销售，主要产品涵盖盆底及妇产康复、生殖康复和抗衰、运动康复及耗材和 信息化产品。目前运动康复产品收入占比较小，暂未对公司业绩产生重大影响。 ...

人民财讯8月12日电，麦澜德(688273)8月12日晚间发布股票交易异常波动公告，公司主要从事盆底及妇 产康复领域相关医疗器械产品的研发、生产、销售，主要产品涵盖盆底及妇产康复、生殖康复和抗衰、 运动康复及耗材和信息化产品。目前运动康复产品收入占比较小，暂未对公司业绩产生重大影响。 ...

Core Viewpoint - The company announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of 30% over three consecutive trading days (August 8, August 11, and August 12, 2025) [1] Company Overview - The company specializes in the research, development, production, and sales of medical devices related to pelvic floor and obstetric rehabilitation [1] - Its main product offerings include pelvic floor and obstetric rehabilitation, reproductive rehabilitation, anti-aging, sports rehabilitation, consumables, and information technology products [1] Financial Impact - Currently, the revenue contribution from sports rehabilitation products is relatively small and has not significantly impacted the company's overall performance [1]

Group 1 - The core viewpoint of the articles highlights the performance and market position of 麦澜德 in the medical device industry, showcasing its recent achievements and financial metrics [1][2] - 麦澜德's stock closed at 29.62 yuan, with a rolling PE ratio of 28.17, marking a new low in 32 days, and a total market capitalization of 29.62 billion yuan [1] - The company ranks 62nd in the medical device industry, which has an average PE ratio of 49.20 and a median of 36.56 [1][2] Group 2 - For Q1 2025, 麦澜德 reported revenue of 1.18 billion yuan, reflecting a year-on-year increase of 13.36%, and a net profit of 3985.97 million yuan, up by 9.85%, with a gross margin of 70.85% [2] - The company specializes in the research, production, sales, and services of products related to pelvic floor and obstetric rehabilitation, focusing on women's health [1] - 麦澜德 has been recognized as a "national manufacturing single champion" and is the first national-level specialized and innovative "little giant" enterprise in its field, indicating strong market competitiveness and innovation capabilities [1]

Core Insights - The company, 麦澜德, closed at 29.24 yuan on May 6, with a 2.78% increase, and a rolling PE ratio of 27.81, marking a new low in 21 days, with a total market capitalization of 2.924 billion yuan [1][2] - In the medical device industry, the average PE ratio is 48.90, with a median of 36.41, placing 麦澜德 at the 64th position [1][2] - As of March 31, 2025, 麦澜德 had 4,927 shareholders, an increase of 433, with an average holding value of 352,800 yuan and an average holding of 27,600 shares [1] Company Overview - 麦澜德 specializes in the research, production, sales, and services of products related to pelvic floor and obstetric rehabilitation, focusing on female pelvic floor and obstetric rehabilitation [1] - The main products include pelvic floor and obstetric rehabilitation products, reproductive rehabilitation products, sports rehabilitation products, consumables, and information technology products [1] - 麦澜德 has been recognized as a "national manufacturing single champion" by the Ministry of Industry and Information Technology, reflecting its specialization, innovation capability, management level, market competitiveness, and social benefits in the field of pelvic floor and obstetric rehabilitation [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 118 million yuan, a year-on-year increase of 13.36%, and a net profit of 39.86 million yuan, up 9.85%, with a gross profit margin of 70.85% [2] - The company's PE ratio (TTM) is 27.81, while the industry average is 48.90, indicating a lower valuation compared to peers [2]